CDK4/6 inhibitor + endocrine therapy
Cut the fuel (oestrogen) and jam the engine (CDK4/6) at the same time.
PFS roughly doubled and OS improved (MONALEESA, MONARCH 2) in advanced HR+ breast cancer; adjuvant benefit (NATALEE, monarchE). One of the most successful combinations in oncology.
Pages like this
not linked directly; found by shared links- PathwayThe cell-cycle engine (cyclins & CDKs)
Shares Ribociclib, Abemaciclib, Oestrogen receptor signalling, Palbociclib.
- IdeaCDK4-selective inhibitors as the new first-line backbone
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
- TermCell cycle
Shares Ribociclib, Abemaciclib, Palbociclib, CDK4/6 inhibitors.
- InstitutionAustrian Breast & Colorectal Cancer Study Group
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares Ribociclib, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
- InstitutionComprehensive Cancer Center Vienna – Medical University of Vienna / AKH
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TermHormone therapy
Shares Oestrogen receptor signalling, Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
- InstitutionGEICAM Spanish Breast Cancer Group
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.